...We Welcome You To The Resverlogix HUB In The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Free
Message: The positive view

A very brief comment but the positive take on this is that it removes the overhang of Dart taking control of thr IP. From memory I believe the IP was pledged as collateral for the loan. It is depressing that we are being diluted at this valuation but at least one of the severe adverse scenarios is off the table. This company, however,  is a case study in how not to run a start up biotech. I believe DM has straight intentions but we have suffered due to his inexperience and naivety. I like him but he should not be leading this company.

Share
New Message
Please login to post a reply